<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541853</url>
  </required_header>
  <id_info>
    <org_study_id>ADPKDCCB</org_study_id>
    <nct_id>NCT00541853</nct_id>
  </id_info>
  <brief_title>CCB Safety Study in Treatment of Hypertension of ADPKD</brief_title>
  <official_title>Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyorin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyorin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the safety and efficacy of calcium channel blocker (CCB) in the treatment
      of hypertension of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients. Angiotensin
      receptor blocker (ARB) was shown to have kidney protecting effects in patients with renal
      diseases including ADPKD, glomerulonephritis and diabetic nephropathy. In case whose blood
      pressure is not normalized by ARB alone, CCB is selected additionally. Recent research
      suggests genetic calcium channel disorder is responsible for the progression of ADPKD. It is
      not examined clinically if CCB treatment has any harmful effect to patients with ADPKD. This
      study examines the safety of Cilnidipine (CCB) in the ADPKD patients whose blood pressure is
      not controlled under 130/85 mmHg by Candesartan (ARB) alone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney Volume measured by MRI.</measure>
    <time_frame>Every year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine, hemodialysis, cardiovascular events and central nervous vascular events</measure>
    <time_frame>any time during study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kidney, Polycystic, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>Candesartan upto 8mg</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan and Cilnidipine</intervention_name>
    <description>Candesartan upto 8mg per day and Cilnidipine upto 20mg per day</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan plus non-CCB agents</intervention_name>
    <description>Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADPKD patients.

          -  Blood pressure measured at out-patient setting is above 130/85 mmHg.

          -  Age between 20 and 60 years old.

          -  Plasma creatinine less than 2.0mg in man and 1.5mg in woman.

          -  Patients give informed consent.

        Exclusion Criteria:

          -  Patients with severe cardiovascular and hepatic disorders.

          -  Patients with complications of central nervous vascular disorders.

          -  Women who are breast feeding and females of childbearing potential who are not using
             acceptable contraceptive methods.

          -  Patients currently engaging in other experimental protocol.

          -  Patients with intracranial aneurysma.

          -  Patients who must use diuretics.

          -  Allergic patients to Candesartan or Cilnidipine.

          -  Patients whose hypertension is not controlled by medication of this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eiji Higashihara, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Kyorin University, School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eiji Higashihara, M.D.</last_name>
    <phone>+81-422-47-5511</phone>
    <phone_ext>5813</phone_ext>
    <email>ehigashi@kyorin-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyorin University School of Medicine</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eiji Higashihara, M.D.</last_name>
      <phone>81+422475511</phone>
      <phone_ext>5813</phone_ext>
      <email>ehigashi@kyorin-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kikuo Nutahara, M.D.</last_name>
      <phone>81-422475511</phone>
      <phone_ext>5815</phone_ext>
      <email>kinuta@kyorin-u.ac.jp</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Urology, National Hospital Organaization Chiba-East Hospital</name>
      <address>
        <city>Chiba, Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koichi Kamura, MD</last_name>
      <phone>81+432615171</phone>
      <phone_ext>7607</phone_ext>
      <email>kamura@cehpnet.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital Kajigaya, Kidney center</name>
      <address>
        <city>Kanagawa</city>
        <zip>213-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshifumi Ubara, MD</last_name>
      <phone>81+448775111</phone>
      <phone_ext>6064</phone_ext>
      <email>ubara@toranomon.gr.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital, Kidney center</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenmei Tkaichi, MD</last_name>
      <phone>81+335881111</phone>
      <phone_ext>7065</phone_ext>
      <email>takaichi@toranomon.gr.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatsuo Hosoya, MD</last_name>
      <phone>81+334331111</phone>
      <phone_ext>3220</phone_ext>
      <email>t-hosoya@jikei.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kazushige Hanaoka, MD</last_name>
      <phone>81+334331111</phone>
      <phone_ext>3221</phone_ext>
      <email>khanaoka@jikei.ac.jp</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Teikyo University, School of Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8605</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shigeo Horie, MD</last_name>
      <phone>81+339641211</phone>
      <email>shorie@med.teikyo-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Satoru Muto, MD</last_name>
      <phone>81+33964-1211</phone>
      <email>muto@med.teikyo-u.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>October 17, 2007</last_update_submitted>
  <last_update_submitted_qc>October 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2007</last_update_posted>
  <keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Angiotensin-2 Receptor Blocker</keyword>
  <keyword>Calcium Channel Blocker</keyword>
  <keyword>Kidney Volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Cilnidipine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 5, 2012</submitted>
    <returned>May 3, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

